Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 18;12:7331–7339. doi: 10.2147/CMAR.S246500

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Huang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

(A) Kaplan–Meier curve of five-year overall survival stratified by reduction ratio of tumor volume at twentieth fraction of radiotherapy in patients treated with definitive CRT, patients with GTVe RR ≥35% had longer five-year OS (73.0% vs 47.7%). (B) Five-year overall survival stratified by pretreatment GTVe, patients with pretreatment GTVe ≤22 cc had better five-year OS (76.3% vs 46.4%). (C) Five-year locoregional recurrence-free survival, pretreatment GTVe ≤22 cc had favorable five-year LRRFS (83.9% vs 64.7%).